One monthly injection for the heart is Repatha, given at a dose of 420 mg by subcutaneous injection.
Repatha (evolocumab) is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. It is approved to lower the risk of heart attack or stroke and to reduce the need for certain heart surgeries in adults with heart disease.
Here's a breakdown:
- Medication: Repatha (evolocumab)
- Purpose: Lowering the risk of heart attack and stroke, and reducing the need for heart surgeries.
- Dosage: 420 mg
- Frequency: Once a month
- Method of Administration: Subcutaneous injection
Repatha is typically prescribed for individuals with:
- Established cardiovascular disease.
- Familial hypercholesterolemia (inherited high cholesterol).
It's important to note that this information is for general knowledge and does not substitute professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment options.
